Jump to content

Ibrutinib: Revision history


For any version listed below, click on its date to view it. For more help, see Help:Page history and Help:Edit summary. (cur) = difference from current version, (prev) = difference from preceding version, m = minor edit, → = section edit, ← = automatic edit summary

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)

16 August 2024

1 July 2024

24 May 2024

2 April 2024

17 March 2024

16 January 2024

20 December 2023

12 December 2023

29 November 2023

14 October 2023

12 September 2023

26 August 2023

21 August 2023

29 June 2023

28 June 2023

10 April 2023

11 March 2023

26 November 2022

23 November 2022

19 November 2022

19 October 2022

25 August 2022

18 May 2022

29 March 2022

22 January 2022

28 December 2021

4 December 2021

3 December 2021

30 November 2021

  • curprev 18:3918:39, 30 November 2021Domochal talk contribs 27,110 bytes −288 Removed mention of generic. Ibrutinib is not available as a generic. This citation does not indicate that it is. Drugs.com has the patents expiring in 2031 at the earliest https://www.drugs.com/availability/generic-imbruvica.html. undo Tag: Visual edit

3 October 2021

20 July 2021

14 July 2021

  • curprev 19:4619:46, 14 July 2021Novem Linguae talk contribs 26,933 bytes +133 {{clarify}} Does it only target malignant B cells, or all B cells? If only malignant B cells, how does it know? undo Tag: Visual edit
  • curprev 10:1210:12, 14 July 2021Shinryuu talk contribs 26,800 bytes +956 Added a brief summary of the mechanism of action to the introductory paragraph as well as a more description to the section "mechanism", and cited the EMA's EPAR as a source for both; rearragend section "mechanism" by importance (label > clinical > preclinical > basic research); further minor changes undo
(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)